Nick Mu

Nick advises companies, investment banks and private equity funds in capital markets transactions, including initial public offerings (IPO), follow-on offerings and regulatory compliance matters, cross-border M&A transactions and other corporate transactions.

Before joining Cooley, Nick worked in the Shanghai office of another leading US law firm.

Nick is a native Mandarin speaker and is fluent in English.

Nick’s matters include representing:

Capital markets

• CapsoVision, a commercial-stage medical device company, in its US$27.5 million IPO and Nasdaq listing*
• Belite Bio, a clinical-stage biotech company, in its US$275 million private placement*
• The sole sponsor CICC and underwriters in a HK$238 million IPO and listing of Qyuns Therapeutics on the Stock Exchange of Hong Kong Limited (HKEX), a clinical-stage biotech company*
• 3D Medicines, a commercialized stage biotech company, in its HK$419 million IPO and listing on HKEX*
• OrbusNeich Medical Group, a commercialized stage medical device company, in its HK$481 million IPO and listing on HKEX*
• eHi Car Services, a leading mobility service and car rental service provider in China, in its US$325 million Regulation S offering of senior notes*

M&A and private equity

• A multinational elevator manufacturing company in its acquisition of majority equity interests in joint ventures*
• A top China-based private equity fund in its early-stage investment in a technology company*
• A multinational communications hardware company in its disposition of equity interests in a joint venture*

*Representation handled before joining Cooley